Prolonged infusion of remimazolam in surgical and medical intensive care unit patients: a pilot pharmacokinetic study.

ABSTRACT:

Background

The pharmacokinetics of prolonged remimazolam infusion in patients undergoing long-term mechanical ventilation remain unclear. This study aimed to evaluate the pharmacokinetics of remimazolam administered continuously for 24 h.

Methods

This open-label pharmacokinetic analysis enrolled patients requiring mechanical ventilation into two groups: the surgical group, which received remimazolam during and after surgery, and the medical ICU group, which received remimazolam in the intensive care unit (ICU). Remimazolam was administered at a fixed rate of 0.1 mg/kg/h for ≥ 24 h, and blood samples were collected at regular intervals. Plasma remimazolam concentrations were measured by tandem mass spectrometry.

Results

Twenty patients (10 in each group) completed the

SUBMITTER: Suzuki Y 

PROVIDER: S-EPMC12805780 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature